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We have developed a fluorescent peptide conjugate 
(TrpNDIRGDfK) based on the coupling of cyclo(RGDfK) to a 
new tryptophan-tagged amino acid naphthalenediimide 
(TrpNDI). Confocal fluorescence microscopy coupled with 10 
fluorescence lifetime imaging (FLIM) mapping, single and 
two-photon fluorescence excitation, lifetime components and 
corresponding decay profiles were used as parameters able to 
investigate qualitatively the cellular behavior regarding the 
molecular environment and biolocalisation  of TrpNDI and 15 
TrpNDI-RGDfK in cancer cells. 
 
Tumor angiogenesis is the process of growing new blood vessels 
that can assist cancerous growths through the supply of nutrients 
and oxygen as well as removing waste products.1 Angiogenesis is 20 
an important feature of the spread of a tumor, given that single 
cancer cells can escape into blood vessels and can also be 
transported to distant sites,2 thus generating secondary tumors. 
Angiogenesis is a potential target for combating cancer as it plays a 
key role in tumor metastasis and growth. The use of specific 25 
compounds that may inhibit new blood vessels formation at the 
tumor site may help to switch off the metastasis, but their intimate 
behavior at the cellular level remains a matter of intense 
investigations: as such, the αvβ3 integrin peptide is one of the most 
important molecular markers involved in the mechanism of cell 30 
adhesion to the extracellular matrix (ECM). The integrin is highly 
expressed during angiogenesis and plays an important role in 
transferring signals from the extra-cellular environment to the 
intracellular compartment.3 The αvβ3 integrin is absent in resting 
endothelial cells and most normal organ systems, rendering it a 35 
potential target for anti-angiogenic cancer therapy. Tumor 
progression and metastasis of breast cancer, glioma, melanoma and 
ovarian carcinoma are all linked to αvβ3 integrin overexpression 
during tumor angiogenesis. It has been found that several proteins 
such as vitronectin, fibrinogen and fibronectin can bind to αvβ3 40 
integrin via the same amino acid sequence arginine-glycine-aspartic 
acid, or RGD.4 It has been shown that cyclo(RGDfK) is one of the 
most prominent structures for development of molecular imaging 
agents for the assessment of αvβ3 expression. This pentapeptide, 
cyclo(-Arg-Gly-Asp-DPhe-Val-), was developed by Kessler and 45 
co-workers to show high affinity and selectivity for αvβ3 integrin.5  
We, and others, have studied the supramolecular chemistry of 
functionalised naphthalene diimides:  NDI molecules have attracted 
considerable attention recently because of excellent electron 
accepting properties and solubility in biocompatible media as well 50 
as organic solvents 6-7. NDIs and their derivatives are flat, aromatic 
molecules which have fluorescent properties, suitable for single- 
and two-photon cellular imaging and are easily functionalisable 
with amino acids.7 These make NDI derivatives attractive 
candidates as building blocks for optical imaging probes, 55 
particularly as NDIs have strong absorption and fluorescence 
emissions in the visible and near-IR wavelengths. Previous work on 
aminoacid-functionalised NDIs showed that, despite quantum 
yields that rather low in aqueous media (less than 0.005 with 
respect to [Ru(bipy)3PF6]’ likely due to non-radiative decay 60 
pathways emerging from aromatic stacking and internal hydrogen 
bonds)8, such materials are taken up by cancer cells in preference 
with respect to healthy cells. Here, the first NDI-peptide imaging 
probe incorporating a cancer specific targeting peptide (cyclic 
RGDfK) and an amino acid (L-Trp) was designed and synthesised 65 
in two simple synthetic steps through the EDC-mediated coupling 
to the strongly fluorescent tryptophan-NDI, which emits broadly in 
both single- and two-photon excitation with maxima above 500 nm.  
 
70 
Scheme 1. Synthesis of tryptophan-NDI-RGDfK, compound 4 
 
To shed light into the fate of bio/medical imaging probes in a 
cellular environment, the uptake of the new compounds 2 and 4 
shown in Scheme 1 was investigated using Fluorescence Lifetime 75 
Imaging Microscopy (FLIM) coupled with multiphoton confocal 
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fluorescence microscopy: this combination of methods, together 
with MTT assays already provided reliable means to probe directly 
the environmental effects upon uptake and biolocalisation of 
aromatic compounds as probes inside living cells.7b, 8-9  
The cyclo-(RGDfK) was chosen in particular for the potential to 5 
selectively bind to prostate cancer cells that overexpress the 
specific target receptor. Furthermore, the NDIs plus cyclo-
(RGDfK) conjugates were used to image cancer cells in vitro.  
A series of purpose-made RGDfK peptides were synthesised 
on a laboratory scale using a standard Fmoc solid phase synthesis 10 
protocol, as described in ESI. The resulting cyclic peptide 3 was 
successfully isolated and characterised by 1H NMR in d6-DMSO 
(including NOESY to verify cyclisation), ESI/MS, MALDI and 
HPLC. A new compound, tryptophan substituted NDI (TrpNDI, 
compound 2) was synthesised from L-Tryptophan and 1,4,5,8-15 
naphtalenetetracarboxylic dianhydride (1), using a rapid and 
straightforward microwave-assisted method (Scheme 1), in 
almost quantitative yield. The molecular structure and 
supramolecular self-assembly of TrpNDI (2) was determined in 
the solid state by single crystal X-ray crystallography (Figure 1). 20 
Crystals suitable for analysis were grown from DMSO and 
synchrotron single crystal X-ray diffraction data was obtained for 
2. The molecules are held together in a hydrogen bonded network 
formed between the tryptophan NH of one molecule and the 
carboxylic carbonyl C=O from neighbouring molecules (N1···O2 25 
2.868 Å, 162.3°; N4···O7 2.862 Å, 168.4°). This supramolecular 
structure is further reinforced by π-π donor-acceptor interactions 
between the tryptophan residue and the NDI core (avg. π···π 
distance 3.233Å, with a 5.9° angle between the two avg. π 
planes). The carboxylic OH is involved in hydrogen bond 30 
interactions with the solvent molecules (DMSO and H2O). 





Figure 1. Molecular structure of Compound 2: (a) Side and (b) crystal 
unit cell packing views of TrpNDI where all hydrogen atoms and a 
disordered solvent molecule (DMSO) have been removed for clarity. (c) a 
view along the a axis rotated by 90° in the b/c plane showing disordered 40 
H2O and DMSO solvating molecules.   
 
With compound 2 in hand, the  corresponding NDI-RGDfK 
conjugate (TrpNDI-RGDfK, 4) was synthesised by coupling the 
EDC-functionalised TrpNDI intermediate (compound 2a, described 45 
in ESI) to the amino group of lysine residue of the deprotected 
cyclic peptide RGDfK (compound 3, as shown in Scheme 1 and 
described in ESI). The novel NDI-peptide conjugate (TrpNDI-
RGDfK) was purified and isolated by semi preparative-HPLC on a 
milligram scale and characterised by MALDI mass spectrometry 50 
(given in ESI).  
The quantum yield of TrpNDI (2) was determined to be 0.002 in 
DMSO, with fluorescein in aqueous 0.1 M NaOH as the 
reference10. This was in line with that found for related NDIs in 
aqueous environments and, since earlier studies on NDIs and 55 
related molecules showed that this does hamper the cellular tracing 
by multiphoton confocal fluorescence imaging, fluorescence 
lifetime imaging microscopy (FLIM) and confocal laser scanning 
microscopy were utilised as the imaging tools of choice for the 
investigations into the probe behavior in living cells.  Furthermore, 60 
MTT assays (ESI) showed that at concentrations of ca. 100 μM 
both compounds 2 and 4 are biocompatible within 48 h observation 
time towards both FEK-4 (a healthy cell line) and PC-3 (prostate 
cancer cell line). ESI describes in full the results of the cellular 
viability assays. The stability of 4 with respect to decomposition 65 
and the retention of corresponding in vitro fluorescence emissions 
were probed in living cells for both TrpNDI (2) and TrpNDI-
RGDfK (4). In order to detect TrpNDI (2) and its RGDfK 
derivative (4) inside cancer cells, FLIM was used here for mapping 
the lifetime of the fluorophores’ emission and also to shed light 70 
upon their cellular biodistribution: this was found, in control 
experiments (described in ESI) to be significantly removed from 
cellular autofluorescence. Interestingly, unlike related NDIs, 
compounds 2 and 4 do not localise in the cells’ nuclei but 
throughout the cytoplasm. Figures 2 and 3 show single photon 75 
confocal laser scanning microscopy (CLSM) images of TrpNDI (2) 
and TrpNDI-RGDfK (4)  in PC-3 cells (ex = 543 nm). TrpNDI (4) 
shows emission upon exciting at either 405 nm, 488 nm and 543 
nm, but TrpNDI-RGDfK only shows emission after exciting at 543 
nm alone. This strongly suggests that following the tagging of 2 80 
with two c(RGDfK) units, the incorporation of this peptide narrows 
the excitation wavelength range necessary to bypass the cellular 




Figure 2. Single-photon laser-scanning confocal microscopy of PC-3 
cells incubated for 25 min. at 37 oC with Compound 2 (100 μM in 1: 99 % 
DMSO: serum free medium): (a-d) (ex = 405 nm, broad observed weak 
emission between 515-530 nm); (e-h) (ex = 488 nm, broad observed 90 
emission both in the red 605-675 nm and green 515-530 nm channels). 
Micrographs a and e show the bright-field images, confirming a ‘healthy’ 
cellular morphology within this experiment time; d and h represent 
overlays of the micrographs (a-b-c) and (e-f-g) respectively.  
Scalebar: 5 μm.  95 
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Figure 3. Single-photon laser-scanning confocal microscopy (ex = 543 
nm, observed emission: 605-675 nm) of PC-3 cells incubated for 25 mins 
at 37 oC with: (a-c) Compound 2 (100 μM in 1: 99 % DMSO: serum free 
medium); (d-f): Compound 4 (100 μM in 1: 99 % DMSO: serum free 5 
medium).  Scalebar 5 µm. The biolocalisation of 2 is uniform throughout 
the cytoplasm whereas that of 4 occurs mainly in punctuated, vesicular 
regions in the cytoplasm.  
 
Two photon imaging experiments were carried out given that 10 
standard dyes co-staining assays were not conclusive in pinpointing 
specific organelles for dyes’ biolocalisation. To investigate the 
effect of the environment on the new probes, lifetime 
measurements were recorded using time-correlated single photon 
counting with an excitation wavelength of 810 nm and the emission 15 
measured at 360-580 nm both in solutions and in living cells. The 
solution measurements of TrpNDI and TrpNDI-RGDfK were 
carried out in DMSO solutions with concentration of 10 mM 
(stock) and 100 μM. Figure 4 shows an overlay of the two-photon 
excitation lifetime decay curves for Compounds TrpNDI 2 and 20 
TrpNDIRGDfK 4 in solution. Lifetime components data were 
processed using SPCImage analysis software (Becker and Hickl, 
Germany) or Edinburgh Instruments F900 TCSPC analysis 
software. The data profile includes the goodness of fit of the decay 
curves as χ2, and the lifetime of each component and their 25 
weighting of each component are given in Tables 1 and 2. The χ2 
value of 1.0 means an optimal single exponential fit of this 
measurement. If the χ2 value is more than 1.3 there is an incomplete 
single exponential fit of this measurement. High χ2 values (>1.5) 
mean either significant noise within the TCSPC setup (electronics 30 
and/or excitation source) or more than one component decay 
profile.  
 
Figure 4. Two-photon time-correlated single photon counting: 
fluorescence decay traces and corresponding fitted curves for the lifetime 35 
determinations (λex = 810 nm, TrpNDI 2, TrpNDIRGDfK 4, 10 mM, pure 
DMSO, 5.7 mW). 
Both TrpNDI 2 and TrpNDI-RGDfK 4 (10 mM stock solutions 
in DMSO, 2P excitation 810 nm) were found to decay as two 
component systems, with minor components (τ2) in the order of 40 
several nanoseconds and major components (τ1) in the order of 
several hundred picoseconds (Table 1). In DMSO, at 100 μM 
Compound 2 was also found to decay as a three component system, 
with a τ1 of 0.1 ns (50%), with a τ2 of 0.7 ns (22.8%) and a τ3 of 3.2 
ns (27.2%), the χ2 was 1.18. The TSPC spectrum of TrpNDI-45 
RGDfK displays a very close decay behavior to that of TrpNDI 
(Table 1, Figure 4 and ESI) and in both cases evidence of some 
aggregation (in line with the X-ray structure observations, Figure 1) 
may account for the extremely short lifetime components present.  
Next, living PC-3 cells were plated on Petri dishes incorporating 50 
a glass cover slip and allowed to adhere for 12 h. Background 
lifetime readings were recorded using fluorescence lifetime 
imaging microscopy (FLIM) before the addition of compound. The 
Petri dishes containing the cells were then mounted on the 
microscope stage and kept at 37 °C during imaging, which was 55 
performed immediately. 
     Table 1. Lifetime decay constants for compounds 2 and 4 point decay 
recorded in pure DMSO solutions (10 mM) 
Compounds τ1 / ns  A1  %  τ2 / ns  A2  %  χ
2 
2 0.6     45.9 2.8 54.1 1.2  
4 0.6  55.4  2.9  44.6 1.0 
Compounds 2 and 4 were dissolved in DMSO and added to the 
cells to achieve a final concentration of dye of 100 μM in EMEM 60 
medium containing 1% DMSO (v/v). Cell uptake was monitored 
after 20 min incubation. Furthermore, precursor compound 2 was 
also incubated at a final concentration of 500 µM and 5 % DMSO 
(v/v) (ESI). Measurements were recorded for the whole field of 
view. The FLIM images obtained for TrpNDI (2) and its RGDfK 65 
derivative (4) are displayed in Figures 5 and 6, including an 
intensity map showing spatial variations in fluorescence 
emission, the lifetime map displaying the distribution of different 
fluorescence decay lifetimes throughout the cellular cytoplasm 
and the profiles of the corresponding lifetime distributions. The 70 
excited state lifetime data (Table 2) show that compounds 1, 2 
and 4 have two lifetime components: a major component A1 for 
(τ1) and a minor component A2 for (τ2). Compound 2 possessed 
lifetime components in PC-3 cells closely matched those 
observed in DMSO solution, with compound 1 displaying a τ1 75 
and τ2 in a cellular environment similar to the τ2 and τ3 found in 
DMSO. Interestingly in PC-3 cells both lifetime components 
were shorter than observed in solution, indicating less stable 
excited state in the cellular environment. Furthermore, a control 
in PC-3 cells showed entirely different lifetime components from 80 
the case when 2 or 4 were incubated with this cell line (Table 2). 
This confirms that the compounds do indeed enter the cells, and 
in line with single photon CLSM measurements, both 2 and 4 
predominantly localise within the cytoplasm with negligible 
nuclear uptake, unlike the related iodine-fundtionalised L-phenyl 85 
alanine NDI reported earlier.8 Interestingly, although both 2 and 4 
are biocompatible with the living cells used hereby within the 
imaging experiments’ timescales, they exhibit different 
fluorescence lifetime values, but which are comparable with 
those resulting from the solution experiments and also show 90 
clearly distinct cellular distributions in vitro. This is not 
surprising given the presence of the RDG targeting peptide in 4, 
molecular size and shape differences and the fact that compound 
4 is more likely than 2 to form large lipophilic cations upon 
protonation.  95 
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        a                                b                             c  
Figure 5. Two-photon laser confocal fluorescence with λex = 810 nm. (a) 
Typical micrograph of PC-3 cells incubated for 20 min at 37 oC with 
compound 2 (100 μM in 1: 99 % DMSO:  EMEM showing compound 2 5 
located throughout in cytoplasm, lifetime mapping; (b) 2-photon 
fluorescence emission intensity image and (c) corresponding average τ 
lifetime distribution curve and lifetime scale-bar. 
Figure 6. Two-photon laser confocal fluorescence with λex = 810 nm. 10 
Typical micrograph of PC-3 cells incubated for 20 min at 37 oC with 
compound 4 (100 μM in 1: 99 % DMSO:  EMEM showing compound 4 
mainly located in vesicular regions in the cytoplasm: lifetime mapping 
(a), intensity image (b), and corresponding average τ lifetime distribution 
curve and lifetime scale-bar  (c). 15 
 Table 2. Typical lifetime decay constants for compounds 2 and 4 evaluated in cellular regions showing uptake in 
PC-3 cancer cells from Figures 5 and 6, as well as Control (ESI). Individual lifetime components and their contributions are given. 
Compound τ1 / ns  FHHM / ns  A1  %  τ2 / ns  FHHM / ns  A2  %  χ
2 
                


















In summary, we developed a new type of molecular imaging 
agent based on the cancer targeting peptide cRGDfK coupled to an 20 
aminoacid functionalised NDI. Fluorescence lifetime mapping, 
fluorescence intensity profile, lifetime components and lifetime 
decay profile were all employed together with MTT assays to 
demonstrate the integrity of these molecular imaging agents in 
cancer cells (PC-3 cells) and their biocompatibility against 25 
cancerous (PC-3) as well as non-cancerous (FEK-4) cell lines.  The 
close similarity between the lifetimes measured for these 
compounds in solution and those determined within cells confirm 
the cellular uptake of such molecules, and offer compelling 
evidence that these are different with respect to those of free, 30 
untreated living cells. These measurements confirm the integrity of 
such NDI compounds within living cells and their cytoplasmic 
distribution. 
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